Celldex Ebit from 2010 to 2024
| CLDX Stock | USD 26.76 1.38 4.90% |
EBIT | First Reported 1989-12-31 | Previous Quarter -46.3 M | Current Value -52.1 M | Quarterly Volatility 15.2 M |
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
Celldex | Ebit |
Latest Celldex Therapeutics' Ebit Growth Pattern
Below is the plot of the Ebit of Celldex Therapeutics over the last few years. It is Celldex Therapeutics' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Celldex Ebit Regression Statistics
| Arithmetic Mean | (82,235,660) | |
| Coefficient Of Variation | (57.79) | |
| Mean Deviation | 39,985,371 | |
| Median | (81,442,000) | |
| Standard Deviation | 47,521,930 | |
| Sample Variance | 2258.3T | |
| Range | 141.2M | |
| R-Value | (0.40) | |
| Mean Square Error | 2040.3T | |
| R-Squared | 0.16 | |
| Significance | 0.14 | |
| Slope | (4,264,601) | |
| Total Sum of Squares | 31616.7T |
Celldex Ebit History
Other Fundumenentals of Celldex Therapeutics
About Celldex Therapeutics Financial Statements
Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -142 M | -134.9 M | |
| EBITDA | -139 M | -132.1 M | |
| Ebt Per Ebit | 0.92 | 0.74 | |
| Ebit Per Revenue | (22.45) | (21.33) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.